Results 21 to 30 of about 11,950 (166)

The Dipyridamole Added to Dual Antiplatelet Therapy in Cerebral Infarction After First Acute Myocardial Infarction: A Nationwide, Case-Control Study

Frontiers in Neurology, 2018
Background and Purpose: No previous study has compared the impact of dipyridamole-based triple antiplatelet therapy on secondary stroke prevention and long-term outcomes to that of dual antiplatelet therapy (DAPT) in patients with acute myocardial ...
Mei-Tzu Wang, Cheng Ken Tsai, Cheng Ken Tsai, Shu-Hung Kuo, Wei-Chun Huang, Wei-Chun Huang, Wei-Chun Huang, Wei-Chun Huang, Wei-Chun Huang, Kun-Chang Lin, Wang-Ting Hung, Chin-Chang Cheng, Chin-Chang Cheng, Chin-Chang Cheng, Pei-Ling Tang, Cheng Chung Hung, Jin-Shiou Yang, Hsin-Li Liang, Guang-Yuan Mar, Chun-Peng Liu, Chun-Peng Liu   +20 more
doaj   +1 more source

Dipyridamole

Reactions Weekly
Ali Hassan R, Patel P.
europepmc   +3 more sources

Dipyridamole treatment is associated with improved renal outcome and patient survival in advanced chronic kidney disease

Kaohsiung Journal of Medical Sciences, 2014
Dipyridamole has been shown to decrease proteinuria and improve renal function progression especially in early chronic kidney disease (CKD) patients with glomerulonephropathy.
Chi-Chih Hung, Mei-Li Yang, Ming-Yen Lin, Hugo You-Hsien Lin, Lee-Moay Lim, Hung-Tien Kuo, Shang-Jyh Hwang, Jer-Chia Tsai, Hung-Chun Chen   +8 more
doaj   +1 more source

Cyclic AMP‐hydrolyzing phosphodiesterase inhibitors potentiate statin‐induced cancer cell death

Molecular Oncology, 2020
Dipyridamole, an antiplatelet drug, has been shown to synergize with statins to induce cancer cell‐specific apoptosis. However, given the polypharmacology of dipyridamole, the mechanism by which it potentiates statin‐induced apoptosis remains unclear ...
Joseph Longo, Aleksandra A. Pandyra, Paweł Stachura, Mark D. Minden, Aaron D. Schimmer, Linda Z. Penn   +5 more
doaj   +1 more source

Early antithrombotic post-discharge therapy using prophylactic DOAC or dipyridamole improves long-term survival and cardiovascular outcomes in hospitalized COVID-19 survivors

Frontiers in Cardiovascular Medicine, 2022
IntroductionCardiovascular events are common in COVID-19. While the use of anticoagulation during hospitalization has been established in current guidelines, recommendations regarding antithrombotic therapy in the post-discharge period are conflicting ...
Lukas J. Motloch, Peter Jirak, Moritz Mirna, Lukas Fiedler, Lukas Fiedler, Paruir A. Davtyan, Irina A. Lakman, Irina A. Lakman, Diana F. Gareeva, Anton V. Tyurin, Ruslan M. Gumerov, Simon T. Matskeplishvili, Valentin N. Pavlov, Benzhi Cai, Kristen Kopp, Albert Topf, Uta C. Hoppe, Rudin Pistulli, Naufal S. Zagidullin   +18 more
doaj   +1 more source

Discovery of Dipyridamole Analogues with Enhanced Metabolic Stability for the Treatment of Idiopathic Pulmonary Fibrosis

Molecules, 2022
Dipyridamole, apart from its well-known antiplatelet and phosphodiesterase inhibitory activities, is a promising old drug for the treatment of pulmonary fibrosis.
Meng-Xing Huang, Yan-Quan Chen, Run-Duo Liu, Yue Huang, Chen Zhang   +4 more
doaj   +1 more source

Current and future use of dipyridamole in patients with COVID-19

Качественная клиническая практика, 2020
Current use of dipyridamole in COVID-19 is mainly based on its antithrombotic activity, since there is no robust clinical effectiveness data. The decision to use dipyridamole in COVID-19 should be individualized, considering the experimental nature of ...
I. S. Burashnikova, V. M. Tsvetov, K. B. Mirzaev, D. A. Sychev   +3 more
doaj   +1 more source

Changes of electrocardiogram and hemodynamics in response to dipyridamole: In vivo comparative analyses using anesthetized beagle dogs and microminipigs

Journal of Pharmacological Sciences, 2018
Microminipigs are expected as a novel animal model for cardiovascular pharmacological experiments. Since inherent vulnerability of coronary circulation of microminipigs has not been characterized, we performed dipyridamole-stress test to both ...
Kentaro Ando, Akira Takahara, Yuji Nakamura, Takeshi Wada, Koki Chiba, Ai Goto, Nur Jaharat Lubna, Mihoko Hagiwara-Nagasawa, Hiroko Izumi-Nakaseko, Kiyotaka Hoshiai, Yasuki Akie, Atsuhiko T. Naito, Atsushi Sugiyama   +12 more
doaj   +1 more source

Dipyridamole-induced adverse effects in myocardial perfusion scans: Dynamic evaluation

International Journal of Cardiology: Heart & Vasculature, 2017
Aim and Background: Dipyridamole-induced stress myocardial perfusion scans (MPS) has been widely used for management of coronary artery disease. The adverse effects of dipyridamole and other stress agents have been evaluated.
Sin-Di Lee, Wei-Chun Huang, Nan-Jing Peng, Chin Hu   +3 more
doaj   +1 more source

Nucleoside Transport Inhibition by Dipyridamole Prevents Angiogenesis Impairment by Homocysteine and Adenosine

Journal of Pharmacy & Pharmaceutical Sciences, 2015
Purpose: Adenosine plays an important role in the pathogenesis of homocysteine-associated vascular complications. Methods: This study examined the effects of dipyridamole, an inhibitor for nucleoside transport, on impaired angiogenic processes caused by ...
Antony Kam, Valentina Razmovski-Naumovski, Xian Zhou, John Troung, Kelvin Chan   +4 more
doaj   +1 more source